The Expression And Effect Of NTR1in Breast Cancer And The Further Study Of Ki67Associated With Breast Cancer Subtypes

Part1ObjectiveTo evaluate the expression of neurotensin receptor1(NTR1) in ductal carcinoma in situ(DCIS) and invasive ductal carcinoma (IDC) of breast cancer, To observe the relationship of their expression with breast cancer pahthological teatures and prognosis and to examine their role in tumor progression, Providing a new method for effective clinical diagnosis and treatment of breast cancer.MethodsImmunohistochemistry was used to examine the expression of NTR1of DCIS(30specimens of low/intermediate grade DCIS and30sprcimens of high grade DCIS) and128specimens of IDC.The breast cancer tissue which expressed NTR1was selected as a positive control,and in the negative control group the NTR1antibody was replaced by PBS.Results(1) In DCIS the expression of NTR1was negative in28cases(46.67%), positive in32cases(53.33), whereas in IDC the corresponding part was37cases(28.91%)、91cases(71.09%) respectively, it was preferentially expressed in IDC compared to DCIS(P<0.05).(2) The expression of NTR1localization was positive correlated with tumor grade(P<0.05),tumor size(P<0.05),lymph node metastases (P<0.05)in IDC. T here was no correlation between the expression of NTR1and tomor pTNM sta ges(P>0.05), ages(P>0.05), Menopausal status(P>0.05) family history(P>0.05).(3) The expression of NTR1localization was positive correlated with recurrence(P<0.05) rate and disease free survivaI(P<0.05).ConclusionCompared to DCIS NTR1was preferentially expressed in IDC, The increase of expression of NTR1localization might participate in the process of invasion of DCIS, The expression of NTR1localization was positive correlated with recurrencerate and disease free survival, This result might provide a new method for effective clinical diagnosis and treatment of breast cancer. Part2ObjectiveTo evaluate the pahthological teatures and recurrence of ER or (and) PR positive breast cancer, and observe the patient’s response to therapy, Discussing Ki67may be an important indicator for further classification in ER or (and) PR positive breast cancer. The further classification might evidence for the selection of individual therapy basis of molecular classification.MethodsUsing immunohistochemistry examine the expression of ER、PR、C-erbB、Ki67in ER or (and) PR positive breast cancer. We retrospectively evaluated conventional clinicopatho-logical factors and treatment modalities of717breast cancer patients, with the median age of53.2years.The breast cancer were divided into three subtype: Luminal A、Luminal B、 Luminal-HER2,717Luminal type of breast cancer cases were retrospectively analyzed clinical pathologic characteristics and clinical treatment. Compareing the recurrence of different subtypes of ER or (and) PR positive breast cancer. Exploration their treatment benefit in the past few years.Results(1)The three breast cancer subtypes were positive correlated with the tumor grade, lymph node status, use of radiotherapy, use of chemotherapy (P<0.05).There was no correlation between the subtypes and age at diagnosis, tumor size, tumor stage, menopausal, use of hormone therapy status, family history (P>0.05)(2)5years disease-free surial of the three breast cancer subtypes were significant differences, disease-free surial of Luminal A、Luminal-HER2and Luminal B subtypes were respectively91.13%,80.54%,83.54%, recurrence rate were respectively8.87%,19.46%和16.46%, Luminal A have relatively the best outcomes in the three subtypes.(3).In Luminal B adjunctive radiotherapy could decrease the risk of relapse (P <0.05).Adjuvant chemotherapies could reduce the relapse for the patients with risk factors and Ki67positive tumors (P<0.05). Adjuvant hormone therapy was an effective treatment for Luminal breast cancer (P<0.05). ConclusionKi67become an indicator for further classification in Luminal breast cancer, use of radiotherapy and chemotherapy can reduce ER or (and) PR positive patients’ recurrence risk of Ki67positive.It provide new visual angle and reference for clinical treatment and improving the prognosis of patients.